Catalog No.
RHK03901
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IP: 1:20, WB: 1:500-1:1000
Target
Deoxyhypusine hydroxylase, hDOHH, DOHH, HLRC1, Deoxyhypusine dioxygenase, HEAT-like repeat-containing protein 1, Deoxyhypusine monooxygenase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9BU89
Applications
IP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R2L52
Development of a reliable, sensitive, and convenient assay for the discovery of new eIF5A hypusination inhibitors., PMID:39937781
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003., PMID:31309259
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)., PMID:26993060
Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation., PMID:24220243
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo., PMID:22624727
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target., PMID:21860023
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA., PMID:20086040
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo., PMID:18852130
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts., PMID:17724141
Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model., PMID:16892169
In vitro studies with bendamustine: enhanced activity in combination with rituximab., PMID:12170426
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases., PMID:11801463
For research use only. Not for human or drug use.
